$VXRT ALT ceo came on CNBC yesterday and they are running over 10%. they haven't even filed IND, and expect to start phase 1 before end of the year. Vaxart is better (pill > nasal spray for eliciting systemic response as well as mucosal protection, and pill is easier than nasal spray administration). Wouldn't be surprised if Vaxart comes on CNBC eventually.
  • 6
6 Likes